» Articles » PMID: 2714684

Immune Mechanisms in Tienilic Acid Associated Hepatotoxicity

Overview
Journal Gut
Specialty Gastroenterology
Date 1989 Apr 1
PMID 2714684
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

In order to investigate the mechanisms underlying the hepatotoxicity associated with tienilic acid (Ticrynafen) ingestion we have looked for evidence of sensitisation to drug altered liver cell determinants using an indirect antibody dependent, cell mediated cytotoxicity assay (ADCC). As targets, hepatocytes were isolated from rabbits pretreated with either tienilic acid or its isomer with or without previous enzyme induction with either phenobarbitone or B-naphthoflavone (BNF). Sera from 16 of 36 patients with presumed tienilic acid hepatotoxicity induced significant cytotoxicity to hepatocytes isolated from rabbits pretreated with BNF and subsequently tienilic acid. Three of 10 sera from patients receiving tienilic acid but without overt liver damage also induced significant cytotoxicity to these hepatocytes, however, although none of 20 normal controls or of 16 patients with other liver diseases did so. Non-organ specific autoantibodies, classified as anti-LKM2, were also detectable. These were present in association with tienilic acid associated antibodies: of the 36 patients with presumed tienilic acid hepatotoxicity, 38% had both antibodies, 18% had only anti-LKM2 antibodies and 9% only tienilic acid associated antibodies. These results suggest that this drug reaction is associated with sensitisation to drug altered liver cell antigens and autoantigens. If ticrynafen associated hepatotoxicity is immune mediated, then one possible mechanism is that the drug induced antigens break tolerance, leading to an immune attack on normal liver cell components.

Citing Articles

Identification of a Shared Cytochrome p4502E1 Epitope Found in Anesthetic Drug-Induced and Viral Hepatitis.

McCarthy E, Vakos A, Cottagiri M, Mantilla J, Santhanam L, Thomas D mSphere. 2018; 3(5).

PMID: 30305319 PMC: 6180222. DOI: 10.1128/mSphere.00453-18.


Diallyl trisulfide protects the liver against hepatotoxicity induced by isoniazid and rifampin in mice by reducing oxidative stress and activating Kupffer cells.

Yang Y, Jiang L, Wang S, Zeng T, Xie K Toxicol Res (Camb). 2018; 5(3):954-962.

PMID: 30090404 PMC: 6060719. DOI: 10.1039/c5tx00440c.


Identification of protein targets of reactive metabolites of tienilic acid in human hepatocytes.

Koen Y, Sarma D, Williams T, Galeva N, Obach R, Hanzlik R Chem Res Toxicol. 2012; 25(5):1145-54.

PMID: 22462724 PMC: 3358484. DOI: 10.1021/tx300103j.


Pathology of flupirtine-induced liver injury: a histological and clinical study of six cases.

Puls F, Agne C, Klein F, Koch M, Rifai K, Manns M Virchows Arch. 2011; 458(6):709-16.

PMID: 21590308 DOI: 10.1007/s00428-011-1087-9.


Autoantibodies as prognostic markers in autoimmune liver disease.

Czaja A Dig Dis Sci. 2010; 55(8):2144-61.

PMID: 20464491 DOI: 10.1007/s10620-010-1268-4.


References
1.
Vergani D, Mieli-Vergani G, Alberti A, Neuberger J, Eddleston A, Davis M . Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N Engl J Med. 1980; 303(2):66-71. DOI: 10.1056/NEJM198007103030202. View

2.
Dubb J, Stote R, MAASS A, Hwang B, FAMILIAR R, Alexander F . Tienilic acid: pharmacokinetics, salicylate interaction and creatinine secretion studies. Postgrad Med J. 1979; 55 Suppl 3:47-57. View

3.
Eugene C, Patriarche C, Bergue A, QUEVAUVILLIERS J . [Tienilic acid as a likely cause of "auto immune" active hepatitis (author's transl)]. Nouv Presse Med. 1980; 9(27):1885-7. View

4.
MECHALI D, Marche C, Metayer J, Saimot G, Matheron S, Rozenbaum W . [Hepatic necrosis secondary to tienilic acid therapy (author's transl)]. Therapie. 1980; 35(2):197-203. View

5.
Bousquet O, Saigot T, Bernard P, Gerbal J, Sarrazin A . [Hepatitis during treatment with tienilic acid (author's transl)]. Therapie. 1980; 35(2):205-8. View